Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Lymphoma

IL-2

Mouse studies suggest a complex composed of an IL-2 mAb and IL-2 could help improve the ability of cancer vaccines to prevent relapse in patients with lymphoma. In mice with minimal residual lymphoma, a cancer vaccine combined with i.p. infusion of the IL-2 mAb-IL-2 complex resulted in 60% of the animals surviving for more than 100 days versus 20% for vaccine alone and 0% for no treatment. Next steps include developing other cytokine-based compounds and testing them with the vaccine in humanized mouse models of cancer.
Heat Biologics Inc. uses its Immune Pan-Antigen Cytotoxic Therapy (ImPACT) technology platform to create vaccines adjuvanted with allogeneic cancer cells that continually secrete heat shock 90 kDa protein b1
(Hsp90B1; GP96; GRP94). The company's most advanced ImPACT cancer vaccine is HS-110, which is in Phase II testing for non-small cell lung cancer (NSCLC).

SciBX 7(17); doi:10.1038/scibx.2014.490
Published online May 1, 2014

Cancer vaccine patented; licensed to Heat Biologics

Newman, R.G. et al. Blood; published online March 31, 2014;
doi:10.1182/blood-2013-08-520775
Contact: Robert B. Levy, University of Miami Miller School of Medicine, Miami, Fla.
e-mail:

rlevy@med.miami.edu